This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
by Zacks Equity Research
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
by Indrajit Bandyopadhyay
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended April 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HealthEquity (HQY) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 19.75% and 3.03%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Curious about HealthEquity (HQY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended April 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
by Zacks Equity Research
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MD vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 89.23% and 22.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -50% and 1.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
by Zacks Equity Research
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
Embecta Corp. (EMBC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 6.06% and 2.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -402.94% and 0.96%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
by Zacks Equity Research
GoodRx (GDRX) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
by Zacks Equity Research
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?
by Zacks Equity Research
STERIS is expected to have experienced an increase in bioprocessing demand in the fourth quarter.
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
by Zacks Equity Research
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
MD vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
by Zacks Equity Research
COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
MD or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Why Is HealthEquity (HQY) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HealthEquity Stock Plunges 13% YTD: Is It Time to Exit or Hold?
by Zacks Equity Research
HQY stock is down more than 13% YTD amid cyber threats and rising costs, but strong HSA fundamentals remain. Is it time to hold or fold? Let's break it down.
Alignment Healthcare (ALHC) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alignment Healthcare (ALHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.